In re: Omega Healthcare Investors, Inc. Securities Litigation

CourtDistrict Court, S.D. New York
DecidedSeptember 28, 2021
Docket1:17-cv-08983
StatusUnknown

This text of In re: Omega Healthcare Investors, Inc. Securities Litigation (In re: Omega Healthcare Investors, Inc. Securities Litigation) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re: Omega Healthcare Investors, Inc. Securities Litigation, (S.D.N.Y. 2021).

Opinion

UNITED STATES DISTRICT COURT

SOUTHERN DISTRICT OF NEW YORK

--------------------------------------X

In re OMEGA HEALTHCARE INVESTORS, INC.

SECURITIES LITIGATION MEMORANDUM AND ORDER --------------------------------------X

This Document Relates To: 17 Civ. 8983 (NRB)

ALL ACTIONS --------------------------------------X NAOMI REICE BUCHWALD UNITED STATES DISTRICT JUDGE

This is the third opinion assessing the sufficiency of lead plaintiffs’ putative class action claims for securities fraud in violation of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder against Omega Healthcare Investors, Inc., its CEO C. Taylor Pickett, its CFO Robert O. Stephenson, and its COO Daniel J. Booth. The Court assumes familiarity with the facts of the case and the legal standards governing motions to dismiss a complaint for securities fraud, as set forth in its prior opinion, In re Omega Healthcare Invs., Inc. Sec. Litig., 375 F. Supp. 3d 496 (S.D.N.Y. 2019) (“Omega I”), and the Second Circuit’s subsequent opinion, Setzer v. Omega Healthcare Invs., Inc., 968 F.3d 204 (2d Cir. 2020) (“Omega II”).1 It is, however, helpful to summarize the procedural history of this action.

1 Unless otherwise noted, the Court incorporates all abbreviations used in Omega I. In Omega I, we found that plaintiffs’ first amended complaint adequately alleged that defendants had made actionable omissions of material facts between May and

October 2017 related to a $15 million Loan that Omega had issued in May 2017 to Orianna, its second-largest healthcare facilities operator. 375 F. Supp. 3d at 507-09. Specifically, we held that in the context of discussing Omega’s financial results in press releases and earnings calls during that period, it was materially misleading for defendants not to disclose the Loan and the fact that Orianna was unable to pay rent to Omega without the Loan proceeds. Id.2 Ultimately, however, we dismissed the first amended complaint because we found that plaintiffs had not alleged a strong inference of scienter related to these omissions. Id. at 509-12. Plaintiffs appealed.

In Omega II, the Second Circuit agreed with our finding that defendants’ failure to disclose the Loan in the context of discussing Orianna’s financial performance and rent

2 We also held that plaintiffs had not adequately alleged a material misrepresentation related to Omega: (1) having its funds from operations or adjusted funds from operations reflect rent collected from Orianna that had been paid using the Loan proceeds; (2) not disclosing Orianna’s financial issues in the context of risk disclosures related to operator bankruptcy in its May 5, 2017 10-Q report; or (3) not disclosing that it had engaged in an evaluation process for determining the impairment of assets related to the Orianna leases in that same report. Omega I, 375 F. Supp. 3d at 507-08. We further rejected plaintiff’s claim that the failure to disclose Orianna’s financial issues in the May 5, 2017 10-Q risk disclosures violated Item 303 of Regulation S-K. Id. at 512-13. payments “rendered statements about Orianna’s performance actionably misleading.” 968 F.3d at 213-14.3 As explained by the Second Circuit, defendants’ omission of the Loan “gave

a false impression of the financial health of one of Omega’s largest assets” and “concealed the extent of Orianna’s solvency problems,” as “Orianna could not pay rent without borrowing from its landlord.” Id. at 214. However, the Second Circuit reversed our decision on scienter, finding that plaintiffs had adequately alleged that defendants’ decision not to disclose the Loan in the context of statements about Orianna’s performance and rent payments was “a sufficiently extreme departure from the standards of ordinary care” to plead a strong inference of scienter under a “conscious recklessness” theory. Id. at 214-16.4 Two key factors informed the panel’s conclusion. First,

given the importance of Orianna to Omega’s overall portfolio, the Second Circuit reasoned that “Omega had to know that

3 Despite plaintiffs’ arguments for reversal of our holding on the universe of material misstatements (see Appellants’ Br., Omega II, No. 19-1095 (2d Cir. June 13, 2019), ECF No. 30 at 25-34), Omega II left undisturbed our dismissal of plaintiffs’ claims based on alleged misstatements and omissions beyond the failure to disclose the Loan. The Second Circuit also declined to address plaintiffs’ argument that “Item 303 imposed an independent duty on Omega to disclose the Loan.” Omega II, 968 F.3d at 214 n.15. 4 Based on concessions made by plaintiffs on appeal, the Second Circuit did not consider our holding that plaintiffs had not adequately alleged scienter based on a “motive and opportunity” theory. Omega II, 968 F.3d at 213 n. 11. revealing the full extent of Orianna’s performance problems would have been troubling news to its investors.” Id. at 215. Second, because Omega knew that the Loan proceeds were

used to pay Orianna’s rent and would be going directly back to Omega’s funds from operations and adjusted funds from operations, the panel concluded that defendants created the illusion that Orianna was “on the road to recovery” despite “ma[king] a conscious decision to not disclose the Loan in order to understate the extent of Orianna’s financial difficulties.” Id. at 215-16. Notably, in reaching its conclusion on scienter, the Second Circuit disagreed with our view on the nature of Omega’s interim disclosures throughout the class period on Orianna’s financial difficulties. While we originally determined that these disclosures were adequate warnings to

investors about Orianna’s financial predicament, see Omega I, 375 F. Supp. 3d at 511, the Second Circuit found that these disclosures about Orianna’s “partial rent payments” “strongly suggest” that defendants intended to “express optimism” about Orianna’s financial prospects and ability to pay rent while “underrepresent[ing] the extent of those very problems,” Omega II, 968 F.3d at 216. In other words, according to the Circuit, these disclosures further concealed the issues affecting Orianna that defendants had failed to disclose. Following remand, the parties entered into a stipulation permitting plaintiffs to file the operative second amended complaint (“Complaint” or “SAC” (ECF No. 80)), which seeks to

move the start of the proposed class back from May 2017 to February 2017 by asserting claims for alleged material misstatements in February 2017.5 Defendants now move to dismiss the Complaint under Federal Rule of Civil Procedure 12(b)(6) on two grounds. (ECF No. 88.) First, they renew their argument that plaintiffs fail to plead a cogent theory of loss causation, an issue that was not reached in either Omega I or Omega II.6 Second, defendants argue that the new allegations of misrepresentations from February 2017 fail to state a claim for securities fraud. Oral argument was held on defendants’ motion on August 30, 2021. For the reasons below, defendants’

motion is granted in part and denied in part.

5 The Second Amended Complaint also bolsters plaintiffs’ allegations of defendants’ scienter by including references to testimony from the related Orianna bankruptcy proceeding that had not been available to plaintiffs when they filed the complaint that was the subject of Omega I. (SAC at 17 n.6.) 6 While defendants urged the Second Circuit to affirm on the alternative ground that the plaintiffs had not adequately alleged loss causation (see Appellees’ Br., Omega II, No. 19-1095 (2d Cir. July 15, 2019), ECF No.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Dura Pharmaceuticals, Inc. v. Broudo
544 U.S. 336 (Supreme Court, 2005)
Lattanzio v. Deloitte & Touche Llp
476 F.3d 147 (Second Circuit, 2007)
Boca Raton Firefighters & Police Pension Fund v. Bahash
506 F. App'x 32 (Second Circuit, 2012)
ATSI Communications, Inc. v. Shaar Fund, Ltd.
493 F.3d 87 (Second Circuit, 2007)
Pollio v. MF Global, Ltd.
608 F. Supp. 2d 564 (S.D. New York, 2009)
In Re Lehman Bros. Securities and Erisa Litigation
799 F. Supp. 2d 258 (S.D. New York, 2011)
In Re Warnaco Group, Inc. Securities Litigation (II)
388 F. Supp. 2d 307 (S.D. New York, 2005)
In Re Initial Public Offering Securities Litigation
358 F. Supp. 2d 189 (S.D. New York, 2004)
In Re Focus Media Holding Ltd. Litigation
701 F. Supp. 2d 534 (S.D. New York, 2010)
In Re Ikon Office Solutions, Inc. Securities Litigation
66 F. Supp. 2d 622 (E.D. Pennsylvania, 1999)
Freudenberg v. E Trade Financial Corp.
712 F. Supp. 2d 171 (S.D. New York, 2010)
Charles Schwab Corp. v. Bank of America Corp.
883 F.3d 68 (Second Circuit, 2018)
In Re Omega Healthcare Inv'rs, Inc. SEC. Litig.
968 F.3d 204 (Second Circuit, 2020)
Nguyen v. Maxpoint Interactive, Inc.
234 F. Supp. 3d 540 (S.D. New York, 2017)
In re Pretium Resources Inc. Securities Litigation
256 F. Supp. 3d 459 (S.D. New York, 2017)
In re Omega Healthcare Investors, Inc.
375 F. Supp. 3d 496 (S.D. Illinois, 2019)
Carpenters Pension Trust Fund of St. Louis v. PLC
750 F.3d 227 (Second Circuit, 2014)
Financial Guaranty Insurance v. Putnam Advisory Co.
783 F.3d 395 (Second Circuit, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
In re: Omega Healthcare Investors, Inc. Securities Litigation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-omega-healthcare-investors-inc-securities-litigation-nysd-2021.